About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Aflibercept in Recurrent or Persistent CNV | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNCT02669953

Aflibercept in Recurrent or Persistent CNV

Age-related macular degeneration (AMD) and diabetic retinopathy are among the most common disorders causing visual disability in elderly people. AMD leads to dysfunction and loss of photoreceptors in ...

Lead sponsor: Medical University of Vienna•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Reinhard Told, MD, PhD

CONTACT

+43140400 reinhard.told@meduniwien.ac.at

Stefan Sacu, Prof. PD. MD

CONTACT

+43140400 stefan.sacu@meduniwien.ac.at

Sponsors

Lead Sponsor

Medical University of Vienna

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adults ≥ 50 years
•Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year
•BCVA \>= 20/400 in the study eye using ETDRS
•Willingness and ability to comply with regular visits
•Signed informed consent

Exclusion Criteria

•Any surgical treatment of the eye within 3 months prior to baseline in the study eye
•History of uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma mediation)
•Aphakia or absence of the posterior capsule (excluding YAG-capsulotomy) in the study eye
•Retinal pigment epithelial tear involving the macula in the study eye

Related studies

RECRUITINGPhase 1

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)

NCT07425522 · Diabetic Macular Edema

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

NCT07308639 · Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)

RECRUITINGPhase 3

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT07449936 · Diabetic Macular Edema, DME, and more

RECRUITINGEARLY Phase 1

Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients

NCT07362927 · Diabetic Macular Edema (DME)

RECRUITINGPhase 3

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT07449923 · Diabetic Macular Edema, DME, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 26, 2024Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment80

Start dateDec 2015

Last updatedNov 26, 2024

Condition

Age Related Macular Degeneration Intravitreal Injections Diabetic Macular Edema

Locations shown

Medical University of Vienna

Vienna

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 26, 2024Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions